The US FDA’s frenetic pace of regulatory activity in the Obama Administration’s waning days may raise concerns that agency efforts to implement the biosimilar approval pathway could hit a lull in the coming months.
However, the 351(k) application workload currently at the agency and the pending reauthorization of the biosimilar user fee program, coupled...